Indiana Patent Litigation Update

Eli Lilly & Co. v. Invagen Pharmaceuticals, Inc.
1:09-cv-00087; filed January 28, 2009 in the Southern District of Indiana

Infringement of U.S. Patent Nos. 6,458,811 (“Benzothiophenes Formulations Containing Same and Methods,” issued October 1, 2002), 6,797,719 (same title, issued September 28, 2004), and 6,894,064 (same title, issued May 17, 2005) following a Paragraph IV certification as part of Invagen’s filing of an ANDA to manufacture a generic version of Lilly’s Evista® (raloxifene, used for the prevention and treatment of osteoporosis in postmenopausal women and for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk of invasive breast cancer).  View the complaint here.

Courtesy of Patent Docs

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s